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Abstract
Background: Overcoming resistance to treatment is an essential issue in many cancers including glioblastoma
(GBM), the deadliest primary tumor of the central nervous system. As dependence on iron is a key feature of tumor
cells, using chelators to reduce iron represents an opportunity to improve conventional GBM therapies. The aim of
the present study was, therefore, to investigate the cytostatic and cytotoxic impact of the new iron chelator
deferasirox (DFX) on human GBM cells in well-defined clinical situations represented by radiation therapy and mild-
hypoxia.
Results: Under experimental normoxic condition (21 % O2), deferasirox (DFX) used at 10 μM for 3 days reduced
proliferation, led cell cycle arrest in S and G2-M phases and induced cytotoxicity and apoptosis in U251 and U87
GBM cells. The abolition of the antineoplastic DFX effects when cells were co-treated with ferric ammonium sulfate
supports the hypothesis that its effects result from its ability to chelate iron. As radiotherapy is the main treatment
for GBM, the combination of DFX and X-ray beam irradiation was also investigated. Irradiation at a dose of 16 Gy
repressed proliferation, cytotoxicity and apoptosis, but only in U251 cells, while no synergy with DFX was observed
in either cell line. Importantly, when the same experiment was conducted in mild-hypoxic conditions (3 % O2), the
antiproliferative and cytotoxic effects of DFX were abolished, and its ability to deplete iron was also impaired.
Conclusions: Taken together, these in vitro results could raise the question of the benefit of using iron chelators in
their native forms under the hypoxic conditions often encountered in solid tumors such as GBM. Developing new
chemistry or a new drug delivery system that would keep DFX active in hypoxic cells may be the next step toward
their application.
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Background
Glioblastomas (GBM), also called grade IV astrocytomas,
are very aggressive primary tumors of the central ner-
vous system. Despite an increase the incidence of up to
seven new cases per 100,000 habitants per year, thera-
peutic approaches have not really evolved in the last
30 years and remain palliative. Treatment generally
consists of surgical resection when possible, followed
by a combination of external beam radiotherapy with
concomitant administration of the orally active
alkylating agent temozolomide (TMZ). Hence, the
prognosis of GBM is still very poor with a median
survival of 14.6 months with radiotherapy amended
with TMZ versus 12.1 months with radiotherapy
alone [1].
To deal with this negative clinical situation, it is im-
portant to find breakthrough therapeutic alternatives
while continuing the development of new adjuvant treat-
ments to improve conventional therapy for GBM. De-
pleting iron levels is a promising approach for GBM.
The anticancer activities of iron depletion are based on
the fact that neoplastic cells require more iron than
normal cells for proliferation [2]. As such, ribonucleotide
reductase, which is involved in DNA synthesis and
which contains a differic iron site, requires iron as a co-
factor to support its activity [2].
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In line with this theory, applying iron chelators that
bind very tightly to iron thereby promoting its excretion
and subsequent depletion in biological systems should
be of major interest [3]. Iron chelation therapy has
already had a significant clinical impact on diseases
other than cancer, primarily to treat iron-overload
diseases but also to treat oxidative stress in neurode-
generative diseases [3, 4].
For many years, the most widely used iron chelator
was the high affinity constant hexadentate ligand desfer-
rioxamine (DFO). More recently, significant efforts have
been made to find new chelators with improved pharma-
cokinetic and pharmacologic properties, among which
the most notable are deferasirox and deferiprone, now
available clinically [5]. The anticancer properties of DFO
and deferiprone have been tested particularly for brain
tumors. Studies conducted at the end of the 1980s in
neuroblastoma cells [6, 7] and in children with neuro-
blastoma [8, 9] showed that DFO has strong antiprolifer-
ative and antineoplastic effects. Deferiprone, a bidentate
iron chelator, has been shown to have antiproliferative
and cytotoxicity activities in neuroblastoma cell lines [7].
However, in vivo, deferiprone fails to reduce tumor
growth in the mice xenograft model of human neuro-
blastoma [10]. In 2005, deferasirox was approved by the
FDA for oral route applications thanks to its high iron
chelating ability, since when its antineoplastic properties
have been tested in numerous human cancer cells and in
preclinical studies [11] (Table 1) but never in the context
of GBM.
The aim of the work was thus to investigate and de-
cipher in vitro the biological effect of the new oral tri-
dentate iron chelator deferasirox (DFX) on two human
glioblastoma cell lines, U87 and U251 cells, in terms of
proliferation, cell cycle, cytotoxicity and apoptosis. Ana-
lyses were performed in conjunction (or not) with exter-
nal beam radiation treatment and in two oxygenation
conditions: experimental normoxia (21 % of oxygen) and




All reagents were obtained from Sigma Aldrich (Saint-
Quentin Fallavie, France), unless stated otherwise.
Cell culture
Glioblastoma U87-MG cells (ATCC® HTB-14™) were
purchased from the American type Culture Collection
(ATCC, LGC Standards, Molsheim, France). U251-MG
cells were a gift from C. Griguer and were originally ob-
tained from Dr. D.D. Bigner (Duke University, Durham,
NC). U251 and U87 cells are routinely cultured in Dul-
becco’s modified Eagle’s medium (DMEM) containing
4.5 g/L glucose and L-glutamine (Lonza, Verviers,
Belgium) supplemented with 10 % (v/v) fetal bovine
serum (FBS) (Lonza, Verviers, Belgium) and a combin-
ation of 100 units/ml penicillin and 100 μg/ml strepto-
mycin. Cells were maintained at 37 °C in a humidified
5 % CO2 atmosphere with 21 % or 3 % of oxygen ob-
tained by N2 supplementation.
DFX treatment
Cells were seeded at 15,000 cells/cm2. Medium was re-
moved and 24 h after splitting was replaced by DMEM
medium with antibiotics and with N1 supplement.
Deferasirox (Euromedex, Mundolsheim, France) was
suspended in DMSO at a concentration of 0.1 M and
used at a final concentration of 10 μM in the cell culture
medium for 3 days.
Irradiation procedure
Cells were seeded at 15,000 cells/cm2. Medium was re-
moved and replaced 24 h after splitting by DMEM
medium with antibiotics and with N1 supplement.
Irradiation was performed with the CP-160 cabinet x-ray
system (Faxitron, Edimex, Le Plessis Grammoire, An-
gers, France) which delivers a dose of 1.5 Gy a minute.
Irradiation was continued for 10.66 min in order to
reach a dose of 16 Gy. The cells were covered during
irradiation.
Proliferation assay
Three days after DFX treatment or irradiation or both,
glioblastoma cells were washed with PBS 1× and fixed in
95 % ethanol / 5 % acetic acid (v/v) for 20 min at 4 °C.
Hoechst 33342 used at 1.5 μg/mL in PBS 1× was incu-
bated for 30 min. For each condition, 10 fields were
counted using a fluorescent microscope (Axiovert 40
CFL Zeiss, Marly le Roi, France) and the number of nu-
clei were determined.
Cytotoxicity assay
Three days after DFX treatment or irradiation or both,
the release of lactate dehydrogenase (LDH) into cell cul-
ture supernatants was measured using a LDH cytotox-
icity detection kit (Roche Diagnostics, Meylan, France)
according to the manufacturer’s instructions. Glioblast-
oma cells treated with Triton X-100 at 0.1 % (v/v) were
used as positive control of cytotoxicity and assigned the
arbitrary value of 100 %.
Caspase 3 activity
Three days after DFX treatment or irradiation or both,
total proteins were isolated from glioblastoma cells by
sonication in a lysis buffer (20 mM PIPES pH 7.2,
100 mM NaCl, 1 mM EDTA, 0.1 % KCl w/v, 10 % su-
crose w/v, DTT 10 mM and PMSF 100 μM). Proteins
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(30 μg) were incubated at 37 °C with 80 μM N-acetyl-
Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (N-acetyl-
DEVD-AMC) and the kinetics of caspase activity was
measured with a Fluoroskan Ascent FL (Thermofisher
scientific, Illkirch, France) at the excitation/emission
wavelength pair of 380/440 nm.
Cell cycle analysis
Cells from three biological replicates were collected,
washed in PBS and fixed in 70 % cold ethanol. Fixed
cells were washed twice in PBS and incubated in a stain-
ing solution containing 100 μg/mL of RNase A and
40 μg/mL of propidium iodide (PI) in PBS for 20 min in
the dark. Subsequently, samples were analysed on a BD
FACSCanto II system (BD Biosciences, Le Pont de Claix,
France) and PI incorporation estimated using the BD
FACSDiva software (BD Biosciences, Le Pont de Claix,
France).
Iron dosage
Iron dosage was performed with the Iron Assay kit (Sigma
Aldrich) according to the manufacturer’s instructions.
Western blot analysis
Total proteins were isolated from GBM cells by sonic-
ation in a lysis buffer composed of 50 mM HEPES,
pH 7.5, 150 mM NaCl, 1 mM EDTA, pH 8, 2.5 mM
EGTA, pH 7.4, 0.1 % Tween 20, 10 % glycerol, 0.1 mM
Table 1 Protocol based on Deferasirox in cancer therapy
Type of cancer Mode of action Ref
Leukemia CALM-AF10 leukemia cells are susceptible to the cytotoxic effects of DFX (5 μM). However, oral chelation induced
by DFX (i.p. 33 mg/kg/day) is not tolerable to leukemic mice and resulted in shortened overall survival.
[32]
DFX (10 to 60 μM) shows antiproliferative activity as well as cytotoxicity toward several myeloma cells (RPMI 8226,
U266 and NCIH929). Mechanisms involved are induced autophagy and repression of mTOR signaling.
[33]
DFX (20–30 mg/kg/day) synergizes with vitamin D to promote monocyte differentiation and to increase overall
survival in elderly patients (≥65 years) with acute myeloid leukemia.
[34]
DFX (12.5 to 100 μM) reduces viability of murine leukemic cells (EL4 and L1210) and induces apoptosis. Mice
bearing L1210 leukemic cells show longer survival than other groups when treated with DFX (p.o. 20 mg/kg/day)
with a tumor size smaller.
[35]
Iron chelation therapy with DFX induces complete remission in a patient with chemotherapy-resistant acute
monocytic leukemia
[36]
DFX (5 to 50 μM) induces apoptosis in myeloid leukemia cells by targeting caspase. [37]
DFX (50 μM) induces apoptosis and inhibits NFKB activity in K562 leukemia cells independently of iron deprivation. [38]
DFX (17 to 50 μM) inhibits proliferation in human myeloid leukemia cell lines (K562, U937, and HL60). Molecular




Iron has been shown to potentiate tumorigenesis in OAC but OAC has traditionally been associated with iron
deficiency anemia. However, patients with OAC could be considered as candidates for a clinical trial of iron
chelation therapy.
[40]
DFX (10 to 40 μM) reduces cellular viability and proliferation of esophageal tumor cell lines (OE33, OE19 and 0E21)
and is able to overcome cisplatin resistance. In human xenograft models, DFX (p.o. 20 mg/kg/day) is able to
suppress tumor growth, which was associated with decreased tumor iron levels.
[41]
Lymphoma DFX (8 to 32 μM) exhibits antitumoral activity against mantle cell lymphoma (HBL-2, Granta-519, Jeko-1). DFX in-
duces apoptosis through caspase-3 activation, down-regulates cyclin D1 and inhibits its related signals, which
leads to a G1-S cell cycle arrest.
[42]
DFX (20 to 100 μM) has dose-dependent cytotoxic effects on human malignant lymphoma cell lines (NCI H28:N78,
Ramos, and Jiyoye) with increased sub-G1 portion and apoptosis.
[43]
Lung Cancer DFX (10 μM) has antiproliferative effect against DMS-53 lung cancer cells and inhibits DMS-53 xenograft growth in
nude mice (p.o. 20 mg/kg/day). Mechanisms involved are increased expression of NDRG1 and CIP1/WAF1 and de-
creased cyclin D1 levels.
[44]
Colorectal cancer DFX (50 μM) inhibits Wnt signaling in colorectal cancer cells (SW480 and DLD-1) and represses cell proliferation in
parallel of the induction of an iron chelation gene signature.
[45]
Liver cancer DFX (10 to 100 μM) represses proliferation of human hepatocarcinoma cells (HepaRG). [46]
In rat (FAO) and human (HUH7) hepatoma cell lines, DFX (10 to 100 μM) decreases cell viability, DNA replication
and the number of the cells in G2-M phase and induces apoptosis. Moreover, DFX inhibits polyamine biosynthesis.
[47]
DFX (10 to 100 μM) induces a cell cycle blockade in G0–G1, decreases cell viability, inhibits DNA replication and
induces DNA fragmentation in the human hepatoma cell line HUH7. Importantly, a higher concentration of DFX is
necessary to induce cytotoxicity in primary human hepatocyte cultures.
[48]
i.v. intravenously, i.p. intraperitoneally, p.o. per os, mTOR mammalian target of rapamycin, NDRG1 N-myc downstream-regulated gene 1, CIP1/WAF1 cyclin-dependent
kinase inhibitor p21, NFKB Nuclear factor-kappaB
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sodium orthovanadate, 1 mM sodium fluoride, 10 mM
glycerophosphate and 0.1 mM phenylmethylsulfonyl
fluoride (PMSF). Proteins (20 μg) were resolved on 4–
20 % Mini-PROTEAN® TGX™ precast polyacrylamide
gels (Bio-rad, Marnes-la-Coquette, France) and trans-
ferred to an Amersham GE Healthcare nitrocellulose
membrane (0.45 μm pore size) (Fisher scientific, Illkirch,
France). The following antibodies were used: a mouse
anti-human Hypoxia-Inducible Factor-1α (HIF-1α)
(610958, clone 54) (BD Biosciences, Le Pont De Claix,
France) and an anti-human Mouse Heat Shock Cognate
Protein 70 (HSC70) (sc-7298, B-6) (Santa Cruz Biotech-
nology, Heidelberg, Germany) was used as a loading
control. These antibodies were diluted at a ratio of re-
spectively 1:1000 and 1:10000, according to the manu-
facturer’s instructions. Goat anti-Mouse IgG Secondary
Antibody, HRP conjugate (Fisher scientific, Illkirch,
France) was used at a dilution of 1:2000. Detection was
performed on SuperSignal™ West Femto Maximum Sen-
sitivity Substrate (Fisher scientific, Illkirch, France) with
a ChemiCapt 3000 imaging system (Vilber Lourmat,
Marne-la-Vallée France).
Statistical analysis
Three independent biological replicates were performed
of all the experiments described in this manuscript. Stat-
istical analyses were performed with R software using
one- or two-way analysis of variance (ANOVA). Differ-
ences were considered significant at a p-value ≤0.05.
Results and discussion
Under experimental normoxic conditions, treatment
with 10 μM of DFX for 3 days significantly inhibited
proliferation of both U251 (Fig. 1a) and U87 (Fig. 1d)
cells in comparison to control cells. The repression of
proliferation was linked to high LDH release (Fig. 1b
and e) and high caspase 3 activity (Fig. 1c and f), sug-
gesting that the antiproliferative effect of DFX is prob-
ably mediated by cell death, including necrosis and
apoptosis. In addition, phase-contrast microscopy pho-
tography clearly showed damage to the cells (Additional
file 1: Figure S1). However, despite the ability of DFX to
repress the proliferation at the same rate in glioblastoma
cells, it led to more LDH release and more caspase 3 ac-
tivity in U251 cells than in U87 cells. Importantly, when
ferric ammonium sulfate (FAC) as Fe3+ donor was sim-
ultaneously added to the cell culture medium with DFX
in stoichiometric proportion (i.e. 5 μM since two mole-
cules of the tridentate DFX chelate one molecule of Fe3
+), the antineoplastic effect of DFX was completely abol-
ished, and, used alone, FAC failed to modulate the
markers. This result confirms that the antineoplastic ef-
fect of DFX can be ascribed to its ability to chelate iron,
thus emphasizing that iron is a key molecule for bio-
logical and biochemical processes.
Since radiotherapy is the main therapy for GBM to date,
the same treatment was performed in combination with
external irradiation. Sixteen hours after the beginning of
DFX treatment, external X-ray beam radiation was applied
at a dose of 16 Gy. Three days after irradiation, a signifi-
cant decrease in proliferation was observed in U251 cells
(Fig. 1a). Moreover, the impact of irradiation on U251 cells
was correlated with the induction of LDH release (Fig. 1b)
and caspase 3 activity (Fig. 1c). However, importantly, ir-
radiation had no significant effect on U87 cells (Fig. 1d
and f). These results suggest that U251 cells are more ra-
diosensitive than U87 cells. These observations are con-
sistent with previous work and may be explained by the
fact that U251 cells have less DNA damage repair activity
of Ape1 than in U87 cells [13].
Upon irradiation, DFX conserved its intrinsic charac-
teristic of an antineoplastic agent in both cell lines, i.e. a
repressor of proliferation, through increased LDH re-
lease and caspase 3 activity, compared to control irradi-
ated cells (Fig. 1). This result showed that irradiation did
not impair the activity of DFX in vitro. Importantly, ir-
radiation did not overload the intrinsic antineoplastic ac-
tivity of DFX nor generate a synergistic effect with DFX.
It is important to note that DFX led to more caspase 3
activity at 0 Gy than at 16 Gy, demonstrating the potent
apoptotic activity of this molecule (Fig. 1c and f). In
addition, iron supplementation upon irradiation did not
modulate the response in terms of proliferation, toxicity
and apoptosis in the two cell lines, showing that excess
of exogenous iron did not affect cell sensitivity to X-rays
(Fig. 1).
As a hypoxic environment is frequently encountered
in GBM due to the presence of areas of necrosis [14]
and since the presence of hypoxic areas in GBM is cor-
related with the aggressive phenotype [15], we decided
to perform the same treatment in a mild-hypoxic brain
tumor environment. Surprisingly, the antiproliverative,
cytotoxic and apoptotic effect of DFX was completely
lost when cells from the two cell lines were cultivated in
3 % of oxygen (Fig. 2). Only the effect of the external
irradiation at a dose of 16 Gy was conserved in U251
cells (Fig. 2a-c). To illustrate these results, no major cells
damages were observed at 3 % of oxygen as shown in
phase-contrast microscopy photography (Additional file 1:
Figure S1). However, DFX led a slight significant induction
of LDH for U251 cells (Fig. 2b) and caspase 3 activity for
U87 cells in non-irradiated and irradiated conditions
(Fig. 2f).
Importantly, same result was observed in human colon
carcinoma, HCT116 cells in terms of proliferation where
DFX treatment (10 μM for 3 days) led to inhibition of
HCT116 proliferation under experimental normoxic


































































































































































































































































































































Fig. 1 Deferasirox inhibits proliferation linked with increased cytotoxicity and apoptosis in glioblastoma cells under normoxic conditions. Number
of nuclei of U251 (a) and U87 (d) glioblastoma cells cultivated at 21 % of oxygen in non-treated condition (CONT) or 3 days after treatment with
5 μM of ferric ammonium citrate (FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC) or with 10 μM of deferasirox (DFX) in non-
irradiated condition (0 Gy) or following irradiation with 16 Gy (16 Gy). The number of nuclei are expressed as mean ± standard deviation (S.D.) (n= 3).
Measure of lactate dehydrogenase (LDH) release into cell culture medium of U251 (b) and U87 (e) glioblastoma cells cultivated at 21 % of oxygen in un-
treated condition (CONT) or 3 days after treatment with 5 μM of ferric ammonium citrate (FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC)
or with 10 μM of deferasirox (DFX) in non-irradiated condition (0 Gy) or following irradiation with 16 Gy (16 Gy). Cytotoxicity is expressed as mean percent-
age ± standard deviation (S.D.) (n= 3) of the total amount of LDH released from cells and relative to glioblastoma cells treated with 0.1 % Triton X-100,
given the arbitrary percentage of 100. DEVD-AMC caspase 3 activity in U251 (c) and U87 (f) glioblastoma cells cultivated at 21 % of oxygen in untreated
condition (CONT) or 3 days after treatment with 5 μM of ferric ammonium citrate (FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC) or with
10 μM of deferasirox (DFX) in non-irradiated condition (0 Gy) or following irradiation with 16 Gy (16 Gy). Caspase 3 activity is expressed as mean arbitrary
units (A.U.) of fluorescence per 30 μg of proteins ± standard error of the mean (SEM) (n= 3). One-way ANOVA was performed between DFX treatment and
CONT, FAC or DFX + FAC conditions in non-irradiated (0 Gy) or irradiated (16 Gy) conditions (*, p-value ≤0.05; **, p-value ≤0.01; ***, p-value ≤0.001). Two-
way ANOVA was performed between non-irradiated (0 Gy) condition and irradiated (16 Gy) condition ($, p-value ≤0.05; $$, p-value ≤0.01; $$$, p-value
≤0.001). Two-way ANOVA was performed between in DFX treatment in non-irradiated condition (0 Gy) and irradiated (16 Gy) condition (£, p-value ≤0.05)
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conditions but was lost in in vitro hypoxic conditions
(Additional file 2: Figure S2).
A mechanism by which iron chelators exert their anti-
neoplastic effects is by targeting iron dependant proteins
that are key component in the progression of the cell
cycle, such as ribonucleotide reductase [2], causing cell
cycle arrest. Therefore, analysis of U251 and U87 cell cy-
cles has been performed in absence or presence of DFX
in combination or not with an irradiation scheme (Fig. 3
and Additional file 3: Figure S3). Under experimental
normoxic conditions, treatment with 10 μM of DFX for












































































































































































































































































































Fig. 2 Antineoplastic effect of deferasirox is totally abolished in glioblastoma cells under mild-hypoxic conditions. The number of nuclei of U251 (a) and
U87 (d) glioblastoma cells cultivated at 3 % of oxygen in untreated condition (CONT) or 3 days after treatment with 5 μM of ferric ammonium citrate
(FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC) or with 10 μM of deferasirox (DFX) in non-irradiated condition (0 Gy) or following irradi-
ation with 16 Gy (16 Gy). The numbers of nuclei are expressed as mean ± standard deviation (SD) (n= 3). Measure of lactate dehydrogenase (LDH) release
into cell culture medium of U251 (b) and U87 (e) glioblastoma cells cultivated at 3 % of oxygen in untreated condition (CONT) or 3 days after treatment
with 5 μM of ferric ammonium citrate (FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC) or with 10 μM of deferasirox (DFX) in non-
irradiated condition (0 Gy) or following irradiation with 16 Gy (16 Gy). Cytotoxicity is expressed as mean percentage ± standard deviation (SD) (n= 3) of the
total amount of LDH released from cells and relative to glioblastoma cells treated 0.1 % Triton X-100, given the arbitrary percentage of 100. DEVD-AMC cas-
pase 3 activity in U251 (c) and U87 (f) glioblastoma cells cultivated at 3 % of oxygen in untreated condition (CONT) or 3 days after treatment with 5 μM of
ferric ammonium citrate (FAC), or with 10 μM of deferasirox and 5 μM of FAC (DFX + FAC) or with 10 μM of deferasirox (DFX) in non-irradiated condition
(0 Gy) or following irradiation with 16 Gy (16 Gy). Caspase 3 activity is expressed as mean arbitrary units (AU) of fluorescence per 30 μg of proteins ± stand-
ard rrror of the mean (SEM) (n= 3). One-way ANOVA was performed between DFX treatment and CONT, FAC or DFX + FAC conditions in non-irradiated
(0 Gy) or irradiated (16 Gy) conditions (*, p-value ≤0.05). Two-way ANOVA was performed between non-irradiated (0 Gy) condition and irradiated
(16 Gy) condition ($, p-value ≤0.05; $$$, p-value ≤0.001)
Legendre et al. BMC Cancer  (2016) 16:51 Page 6 of 11
in S phase and a slight accumulation in G2-M phase
(Fig. 3a). Concerning U87 cells, 10 μM of DFX induced an
important accumulation of cells in G2-M phase and a
slight accumulation in S phases (Fig. 3c). This increase in
the GBM cell number in S and G2-M phases was corre-
lated to a diminution in the number of cells in G0-G1
phase (Fig. 3a and c). Importantly, the capacity of DFX to
profoundly affect cell cycle distribution under experimen-
tal normoxic condition is lost at 3 % of oxygen (Fig. 3b
and d) except for U251 cells where a slight accumulation
in phase S is still observed at 3 % of oxygen (Fig. 3b).
Three days after irradiation, elevated accumulation of
cells in the G2-M phase of the cell cycle is observed for
both GBM cells and both conditions of oxygenation and
accumulation in S phase is also observed but only for
U251 cells (Fig. 3). Interestingly, although irradiation did
not affect significantly U87 proliferation (Fig. 1), an ac-
cumulation in G2-M phase is observed (Fig. 3c and d).
Finally, when irradiation was combined to DFX, at
21 % of oxygen, cell cycle profiles are very similar to the
one obtained with DFX alone (Fig. 3a and c and
Additional file 3: Figure S3). In contrast, at 3 % of oxy-
gen, the combination of irradiation with DFX resulted in
a cell cycle profile rather similar to the one obtained
with radiation alone, while DFX was even capable to
slightly reduce the impact of radiations on cell accumu-
lation in G2-M phase.
In this last condition, the increase in S phase, particu-
larly for U251 cells, revealed an effect of the iron chela-
tor that was initially hidden in the overall analysis of cell
proliferation (Fig. 3b and d and Additional file 3: Figure
S3). As such, DFX seems to mainly interfere with S-
phase, which has already been related to the specific ex-
pression of the ribonucleotide reductase [2], requiring
iron for its activity which catalyzes the rate limiting step
in the production of deoxyribonucleotides needed for
DNA synthesis. Meanwhile, irradiation leads more a G2-
M blockade, important phase for DNA damage check-
point upstream DNA repair or cell death. However,
whatever their intrinsic impact, nearly abolish for DFX
used alone at 3 %, DFX and irradiation did not presented











0 Gy 16 Gy
21% O2 3% O2
0 Gy 16 Gy

























































































































21% O2 3% O2
U87 
c d % G0-G1
% S
% G2-M
Fig. 3 Deferasirox induced S and G2-M cell cycle arrest in glioblastoma cells but only under normoxic conditions. Cell cycle distribution in U251
glioblastoma cells cultivated at 21 % (a) or 3 % (b) of oxygen and in U87 glioblastoma cells cultivated at 21 % (c) or 3 % (d) of oxygen
in untreated condition (CONT) or 3 days after treatment with 10 μM of deferasirox (DFX) in non-irradiated condition (0 Gy) or following
irradiation with 16 Gy (16 Gy). Cell cycle distribution is expressed as percentage of cells in G0-G1, S and G2-M phases
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To better understand why the effect of DFX is lost at
3 % of oxygen in vitro, iron dosage was performed. The
iron contents measured in both GBM cells are in line
with values found in primary rat astrocytes (9.3 ±
1.2 nmol per mg protein) [16] (Fig. 4). DFX treatment at
10 μM for 3 days in normoxic condition led to signifi-
cant intracellular iron depletion in both cell lines (Fig. 4a
and c). Moreover, irradiation significantly repressed
intracellular iron contents but only in U251 cells in nor-
moxic condition (Fig. 4a). Importantly, no repression of
iron content by DFX was measured with 3 % O2 al-
though there was no difference between the total con-
centration of iron in the two oxygenation conditions
(Fig. 4b and d). This result suggests that the effect of
DFX on intracellular iron depletion observed at 21 % of
oxygen is absent at 3 % of oxygen. Since the antineoplas-
tic effect of DFX is due to its ability to chelate iron, as
FAC addition abolishes the toxicity of DFX, this could
explain the absence of antineoplastic effect of DFX at
3 % of oxygen. As oxidation is less frequent in hypoxic
condition than in normoxic condition [17], it is possible
that at 3 % of oxygen, more Fe2+ is present than Fe3+.
As DFX is selective for Fe3+ chelation [18], this hypoth-
esis could explain the loss of DFX effect in mild-hypoxic
condition. In order to confirm this hypothesis, an iron
dosage to distinguish the ferrous (Fe2+) and ferric (Fe3
+) forms should be used to get round the limit of detec-
tion of these two forms of iron.
The loss of antineoplastic activity of DFX in an in-vitro
mild-hypoxia environment could raise the question of the
benefits of using iron chelators in anticancer therapy where
the tumor is often hypoxic [12]. The synthesis of iron chela-
tors that efficient only in hypoxic cells, such as bioreductive
prodrugs [17], might overcome this limitation. Another al-
ternative would be the synthesis of iron chelators that are
only active in cancer cells. This has already been achieved in
neurodegenerative diseases where iron accumulation has
been clearly linked to these diseases [4]. In Alzheimer’s dis-
ease, the finding that acetylcholinesterase (AChE) colocalizes
with amyloid-β and accelerates its aggregation has led to the
development of a new class of selective AChE inhibitors






























































































































































Fig. 4 Intracellular iron concentration is depleted by both deferasirox and irradiation in U251 cells but only under normoxic condition. Intracellular iron
concentration in U251 glioblastoma cells cultivated at 21 % (a) or 3 % (b) of oxygen and in U87 glioblastoma cells cultivated at 21 % (c) or 3 % (d) of
oxygen in untreated condition (CONT) or 3 days after treatment with 10 μM of deferasirox (DFX) in non-irradiated condition (0 Gy) or following irradi-
ation with 16 Gy (16 Gy). Intracellular iron concentration is expressed in nmol per mg of protein as mean ± standard deviation (SD) (n = 3).
One-way ANOVA was performed between DFX treatment and CONT in non-irradiated (0 Gy) or irradiated (16 Gy) conditions (*, p-value
≤0.05; ***, p-value ≤0.001). Two-way ANOVA was performed between non-irradiated (0 Gy) condition and irradiated (16 Gy) condition
($$$, p-value ≤0.001)
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HLA20A exhibits low affinity for metal ions, but can be ac-
tivated following AChE cleavage to liberate an active chela-
tor and an AChE inhibitor [19]. The active molecule
HLA20 possesses neuroprotective properties both in vitro
and in vivo with the ability to inhibit β-amyloid aggregation
induced by metal ions [19]. An additional strategy could be
to take advantage of cancer cell metabolism to build a site-
directed iron chelator. In this context, the synthesis of a new
generation of iron chelators such as quilamines has pro-
duced encouraging results [20]. Quilamines are linked to
linear polyamine vectors that use the polyamine transport
system, which is overexpressed in most cancer cells [20].
Another dilemma linked with iron chelators is that
iron depletion may inhibit prolyl hydroxylase domain
(PHD) enzyme activity and therefore activate the
hypoxia-inducible factor-1 (HIF-1) pathway, which is im-
plicated in tumor aggressiveness and invasion [21]. In-
deed, in both GBM cells, HIF-1α protein stabilization
has been observed following DFX treatment in normoxic
condition (Fig. 5). Importantly, the mild-hypoxic condi-
tion led to stabilization of HIF-1α in U87 cells (Fig. 5b)
but not in U251 cells (Fig. 5a), suggesting that in this
GBM cell line, an oxygen concentration of 3 % is not
low enough to observe intracellular accumulation of
HIF-1α. However, at this low level of oxygen, DFX was
still able to stabilize the HIF-1α protein in U251 cells
and the same trend was observed in U87 despite the fact
that the stabilization was largely masked by the high
level of HIF-1α in these low oxygen conditions. More-
over, irradiation did not significantly impact HIF-1α ex-
pression or DFX-mediated HIF-1α stabilization in either
type of cell. Finally, HIF-1α protein stabilization medi-
ated by DFX observed in all the conditions tested (Fig. 5),
suggests that the difference in the antineoplastic effect
by DFX observed at 21 and 3 % of oxygen should not be
attributed to HIF-1 signaling. The consequence of this
HIF-1α stabilization could be dramatic for anticancer
therapy. Indeed, it has been shown that iron depletion
by desferrioxamine (DFO), which leads to HIF-1 activa-
tion and expression of urokinase plasminogen activator
(uPAR) and matrix metallopeptidase 2 (MMP2), en-
hanced invasion of GBM cells by degrading the extracel-
lular matrix (ECM) [22]. In addition, in clinical trials
with DFO, toxicities including edema were reported
[23], probably due to its ability to increase the potent
angiogenic factor vascular endothelial growth factor
(VEGF) [24], a well characterized HIF-1 target gene.
Taken together, these data underline the need for cau-
tion when using chelators in cancer therapy, particularly
for tumors with high invasive potential.
Moreover, it is still difficult to predict if iron chelation
is able to affect all the GBM tumor margins and how
homogeneously tumor mass rapid dividing cells and
glioblastoma stem cells (GSC) would respond to iron
chelation. Concerning GSC, chelation therapy may have
an impact on cancer stem cells since it has been recently
shown that iron dependency is enhanced in GSC [25].
However, it is important to notice that GBM tumors are
composed of GSC plastic cells (defined as proliferative,
symmetrically dividing and less invasive cells) and GSC
rigid cells (defined as quiescent, asymmetrically dividing
and more invasive cells) [26]. Since iron chelators prefer-
entially target cells with high proliferative capacity, DFX
might not be selective for GSC rigid cells responsible for
tumor recurrence. Taken together, impact of DFX on
GBM cells and GSC warrants further investigation.
Another limit to using iron chelators in brain tumors
is the difficulty in crossing the blood–brain barrier
(BBB). In neurodegenerative diseases, Novartis claims
improved penetration of DFX into the brain through the
co-administration of an efflux protein inhibitor in the
patent US20090306160A1. Among other alternatives,
drug delivery nanosystems derived from nanotechnol-
ogies are perhaps the most appropriate and potentially
the most useful in this biological context [27]. Drugs en-
capsulated in nanoparticles may be more soluble, and
have improved biological barrier crossing properties and
better controlled release kinetics, with substantial clin-
ical advantages including dose reduction, prevention of
side effects and improvement of bioavailability within
CONT DFX  CONT DFX  CONT DFX   CONT  DFX  
HIF-1α
HSC-70
0 Gy 16 Gy
21% O2
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Fig. 5 Deferasirox induced hypoxia-inducible factor -1α (HIF-1α)
protein stabilization. Levels of hypoxia-inducible factor -1α (HIF-1α)
protein and heat shock cognate protein 70 (HSC70) protein used as
loading control protein in U251 glioblastoma cells cultivated at 21 % of
oxygen or 3 % of oxygen (a) and in U87 glioblastoma cells cultivated
at 21 % of oxygen or 3 % of oxygen (b) in untreated condition (CONT)
or 3 days after treatment with 10 μM of deferasirox (DFX) in non-
irradiated condition (0 Gy) or following irradiation with 16 Gy (16 Gy).
Western blot data represent one of three independent experiments
with comparable results
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the targeted tumor cells [27]. Such nano-objects can ei-
ther be implanted inside the tumor or within the resec-
tion cavity or, alternatively, delivered via the blood to the
CNS tumor site. Brain locoregional active targeting by
direct infusion by convection-enhanced delivery (CED)
into the brain could lead to a major breakthrough in effi-
cacy while allowing optimum specificity and safety [28].
Concerning iron chelation therapies, some studies of
nano-carriers are currently being conducted for use in neu-
rodegenerative diseases [29–31]. Conjugating a derivative
of deferiprone with nanoparticles did not alter its ability to
chelate iron. This nano-deferiprone analog conjugate was
shown to be able to inhibit amyloid-β aggregation in vitro
and to protect neuronal cells from amyloid-β-associated
neurotoxicity [30, 31]. DFX has been conjugated to lactofer-
rin, which was able to cross the BBB via its receptors. The
neuroprotective effects of this nano-object have been
assessed in vitro and in vivo. The results revealed a signifi-
cant reduction in learning deficits induced by amyloid-β in-
jection in a rat model of Alzheimer’s disease [29]. However,
none of these objects have yet been tested in the context of
brain tumors, including in GBM, and locoregional applica-
tion should probably be improved.
Conclusions
Taken together, the results of the present work underline
the fact that iron depletion by iron chelators and their
application in anticancer strategies is much more com-
plex than initially thought. Since DFX does not synergize
with irradiation and as low oxygen tension reverses its
activity in vitro, developing new chemistry or a drug de-
livery system that would keep DFX active in hypoxic
cells should be the next step in its clinical development.
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